JP2024514010A5 - - Google Patents
Info
- Publication number
- JP2024514010A5 JP2024514010A5 JP2023563854A JP2023563854A JP2024514010A5 JP 2024514010 A5 JP2024514010 A5 JP 2024514010A5 JP 2023563854 A JP2023563854 A JP 2023563854A JP 2023563854 A JP2023563854 A JP 2023563854A JP 2024514010 A5 JP2024514010 A5 JP 2024514010A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- heterocyclyl
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024217755A JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177775P | 2021-04-21 | 2021-04-21 | |
| US63/177,775 | 2021-04-21 | ||
| US202163285410P | 2021-12-02 | 2021-12-02 | |
| US63/285,410 | 2021-12-02 | ||
| PCT/US2022/025329 WO2022225914A1 (en) | 2021-04-21 | 2022-04-19 | Carboxy-benzimidazole glp-1r modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024217755A Division JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514010A JP2024514010A (ja) | 2024-03-27 |
| JP2024514010A5 true JP2024514010A5 (https=) | 2024-04-24 |
| JP7642098B2 JP7642098B2 (ja) | 2025-03-07 |
Family
ID=81654849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563854A Active JP7642098B2 (ja) | 2021-04-21 | 2022-04-19 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
| JP2024217755A Pending JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024217755A Pending JP2025028177A (ja) | 2021-04-21 | 2024-12-12 | カルボキシ－ベンズイミダゾールｇｌｐ－１ｒ調節化合物 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20230021705A1 (https=) |
| EP (2) | EP4520393A3 (https=) |
| JP (2) | JP7642098B2 (https=) |
| KR (1) | KR20230173719A (https=) |
| AU (2) | AU2022260487B2 (https=) |
| BR (1) | BR112023021978A2 (https=) |
| CA (1) | CA3216372A1 (https=) |
| CL (1) | CL2023003113A1 (https=) |
| CO (1) | CO2023013766A2 (https=) |
| CR (1) | CR20230493A (https=) |
| DK (1) | DK4271674T6 (https=) |
| DO (2) | DOP2023000231A (https=) |
| ES (1) | ES3025032T7 (https=) |
| FI (1) | FI4271674T6 (https=) |
| HR (1) | HRP20250415T4 (https=) |
| HU (1) | HUE071198T2 (https=) |
| IL (1) | IL307768A (https=) |
| LT (1) | LT4271674T (https=) |
| MX (1) | MX2023012419A (https=) |
| PE (1) | PE20232051A1 (https=) |
| PH (1) | PH12023552861A1 (https=) |
| PL (1) | PL4271674T6 (https=) |
| PT (1) | PT4271674T (https=) |
| SI (1) | SI4271674T2 (https=) |
| TW (2) | TWI819577B (https=) |
| UA (1) | UA130357C2 (https=) |
| WO (1) | WO2022225914A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| IL309235A (en) * | 2021-06-24 | 2024-02-01 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Glp-1 receptor agonist and composition and use thereof |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| CN118496200A (zh) * | 2023-02-14 | 2024-08-16 | 成都康弘药业集团股份有限公司 | 吲唑啉酮类化合物及其制备方法和用途 |
| EP4731245A1 (en) * | 2023-06-23 | 2026-04-29 | Merck Sharp & Dohme LLC | Use of a long-acting oxyntomodulin derivative for treament of fatty liver disease |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2025226506A1 (en) * | 2024-04-23 | 2025-10-30 | Protagonist Therapeutics, Inc. | Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| KR102841983B1 (ko) * | 2019-11-04 | 2025-08-04 | 주식회사 엘지화학 | 광변조 디바이스의 제조 방법 |
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| WO2022078152A1 (zh) * | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
-
2022
- 2022-04-19 ES ES22723850T patent/ES3025032T7/es active Active
- 2022-04-19 PT PT227238508T patent/PT4271674T/pt unknown
- 2022-04-19 MX MX2023012419A patent/MX2023012419A/es unknown
- 2022-04-19 CA CA3216372A patent/CA3216372A1/en active Pending
- 2022-04-19 PL PL22723850.8T patent/PL4271674T6/pl unknown
- 2022-04-19 BR BR112023021978A patent/BR112023021978A2/pt unknown
- 2022-04-19 HU HUE22723850A patent/HUE071198T2/hu unknown
- 2022-04-19 EP EP24218624.5A patent/EP4520393A3/en active Pending
- 2022-04-19 JP JP2023563854A patent/JP7642098B2/ja active Active
- 2022-04-19 PH PH1/2023/552861A patent/PH12023552861A1/en unknown
- 2022-04-19 IL IL307768A patent/IL307768A/en unknown
- 2022-04-19 PE PE2023002901A patent/PE20232051A1/es unknown
- 2022-04-19 UA UAA202305451A patent/UA130357C2/uk unknown
- 2022-04-19 DK DK22723850.8T patent/DK4271674T6/da active
- 2022-04-19 SI SI202230115T patent/SI4271674T2/sl unknown
- 2022-04-19 CR CR20230493A patent/CR20230493A/es unknown
- 2022-04-19 US US17/723,758 patent/US20230021705A1/en not_active Abandoned
- 2022-04-19 FI FIEP22723850.8T patent/FI4271674T6/fi active
- 2022-04-19 AU AU2022260487A patent/AU2022260487B2/en active Active
- 2022-04-19 EP EP22723850.8A patent/EP4271674B9/en active Active
- 2022-04-19 HR HRP20250415TT patent/HRP20250415T4/hr unknown
- 2022-04-19 WO PCT/US2022/025329 patent/WO2022225914A1/en not_active Ceased
- 2022-04-19 KR KR1020237040113A patent/KR20230173719A/ko active Pending
- 2022-04-19 LT LTEPPCT/US2022/025329T patent/LT4271674T/lt unknown
- 2022-04-20 TW TW111114937A patent/TWI819577B/zh active
- 2022-04-20 TW TW112137479A patent/TW202402752A/zh unknown
-
2023
- 2023-10-19 CL CL2023003113A patent/CL2023003113A1/es unknown
- 2023-10-19 DO DO2023000231A patent/DOP2023000231A/es unknown
- 2023-10-19 CO CONC2023/0013766A patent/CO2023013766A2/es unknown
-
2024
- 2024-12-12 JP JP2024217755A patent/JP2025028177A/ja active Pending
-
2025
- 2025-03-20 US US19/085,239 patent/US20250312352A1/en active Pending
- 2025-05-12 DO DO2025000109A patent/DOP2025000109A/es unknown
- 2025-11-27 AU AU2025271403A patent/AU2025271403A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514010A5 (https=) | ||
| JP2024514009A5 (https=) | ||
| HRP20250415T1 (hr) | Modulirajući spojevi karboksi-benzimidazola glp-1r | |
| CN115335374B (zh) | Glp-1r调节化合物 | |
| US10941113B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
| ES2713566T3 (es) | Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II | |
| CN1195526C (zh) | 含对映体纯β－D－二氧戊环核苷的药物产品 | |
| US10160743B2 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| JP2023540609A5 (https=) | ||
| JP2023515404A5 (https=) | ||
| JP2019069940A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| US6525033B1 (en) | Nucleosides with anti-hepatitis B virus activity | |
| JP2021095409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
| US20120046305A1 (en) | Methods and compositions for treating respiratory disorders | |
| KR20240068737A (ko) | Glp-1r 효능제로서의 벤즈이미다졸 카복실산 | |
| JP2019517478A5 (https=) | ||
| JP2018531919A (ja) | Ｂ型肝炎ウイルスコアタンパク質モジュレーター | |
| CA2251580A1 (en) | Amides as npy5 receptor antagonists | |
| JPWO2010027005A1 (ja) | 置換アミン誘導体及びこれを有効成分とする医薬組成物 | |
| JP2009102334A (ja) | 神経変性疾患治療剤 | |
| EP2563777A2 (en) | Inverse agonists and neutral antagonists for the tsh receptor | |
| TW201522291A (zh) | 胍基苯甲酸酯化合物 | |
| US6245817B1 (en) | NPY5 receptor antagonists and methods for using same | |
| JP2017523211A (ja) | 新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法 | |
| WO2016024598A1 (ja) | 新規テトラヒドロピリドピリミジノン誘導体 |